SOPHiA GENETICS Balance Sheet Health
Financial Health criteria checks 6/6
SOPHiA GENETICS has a total shareholder equity of $96.5M and total debt of $13.2M, which brings its debt-to-equity ratio to 13.7%. Its total assets and total liabilities are $155.3M and $58.8M respectively.
Key information
13.7%
Debt to equity ratio
US$13.24m
Debt
| Interest coverage ratio | n/a |
| Cash | US$80.23m |
| Equity | US$96.49m |
| Total liabilities | US$58.82m |
| Total assets | US$155.31m |
Recent financial health updates
Is SOPHiA GENETICS (NASDAQ:SOPH) A Risky Investment?
Oct 03
Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Dec 27Is SOPHiA GENETICS (NASDAQ:SOPH) In A Good Position To Invest In Growth?
Aug 08Here's Why We're Watching SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Dec 15We're Hopeful That SOPHiA GENETICS (NASDAQ:SOPH) Will Use Its Cash Wisely
Jul 01We Think SOPHiA GENETICS (NASDAQ:SOPH) Can Afford To Drive Business Growth
Mar 10Recent updates
Shareholders Should Be Pleased With SOPHiA GENETICS SA's (NASDAQ:SOPH) Price
Jan 10Is SOPHiA GENETICS (NASDAQ:SOPH) A Risky Investment?
Oct 03SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported, And Analysts Assigned A US$6.00 Price Target
Aug 09Investors Still Waiting For A Pull Back In SOPHiA GENETICS SA (NASDAQ:SOPH)
Aug 08SOPHiA GENETICS SA (NASDAQ:SOPH) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mar 09Sophia Genetics: Breakthrough Potential In A Cautious Healthcare Sector
Feb 12Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Dec 27Why Investors Shouldn't Be Surprised By SOPHiA GENETICS SA's (NASDAQ:SOPH) 35% Share Price Surge
Nov 09Is SOPHiA GENETICS (NASDAQ:SOPH) In A Good Position To Invest In Growth?
Aug 08Here's Why We're Watching SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Dec 15SOPHiA GENETICS partnering with Boundless Bio on oncogene cancer therapies
Sep 21SOPHiA Genetics GAAP EPS of -$0.39 in-line, revenue of $11.7M misses by $0.25M
Aug 09We're Hopeful That SOPHiA GENETICS (NASDAQ:SOPH) Will Use Its Cash Wisely
Jul 01SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 18We Think SOPHiA GENETICS (NASDAQ:SOPH) Can Afford To Drive Business Growth
Mar 10Here's Why We're Not Too Worried About SOPHiA GENETICS' (NASDAQ:SOPH) Cash Burn Situation
Nov 24Financial Position Analysis
Short Term Liabilities: SOPH's short term assets ($99.4M) exceed its short term liabilities ($26.8M).
Long Term Liabilities: SOPH's short term assets ($99.4M) exceed its long term liabilities ($32.0M).
Debt to Equity History and Analysis
Debt Level: SOPH has more cash than its total debt.
Reducing Debt: SOPH's debt to equity ratio has reduced from 17.2% to 13.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SOPH has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SOPH has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 5.5% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/16 02:28 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SOPHiA GENETICS SA is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |
| Katie Tryhane | Credit Suisse |